SG11201809677XA - Cd200 mutant and its uses - Google Patents

Cd200 mutant and its uses

Info

Publication number
SG11201809677XA
SG11201809677XA SG11201809677XA SG11201809677XA SG11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA
Authority
SG
Singapore
Prior art keywords
international
lane
protein
blenheim
freeland
Prior art date
Application number
SG11201809677XA
Inventor
Philip Huxley
Joseph Sheridan
Jonathan Heal
Original Assignee
Ducentis Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ducentis Biotherapeutics Ltd filed Critical Ducentis Biotherapeutics Ltd
Publication of SG11201809677XA publication Critical patent/SG11201809677XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111101011111111111 0111011111011111111011111101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/194941 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: (74) Agent: GIBSON, Mark et al.; Sagittarius IP, Three Globe- C07K 14/705 (2006.01) A61K 38/17(2006.01) side, Fieldhouse Lane, Marlow Buckinghamshire SL7 1HZ C12N 15/62 (2006.01) (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/GB2017/051303 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 10 May 2017 (10.05.2017) CA, DZ, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (26) Publication Language: English KW, MK, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 1608197.8 10 May 2016 (10.05.2016) GB SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: DUCENTIS BIOTHERAPEUTICS LTD. [GB/GB]; 9 Blenheim Lane, Freeland, Witney Oxfordshire (84) Designated States (unless otherwise indicated, for every OX29 8AW (GB). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: HUXLEY, Philip; c/o Ducentis Biotherapeu-UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, tics Ltd., 9 Blenheim Lane, Freeland, Witney Oxfordshire TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — OX29 8AW (GB). SHERIDAN, Joseph; c/o Ducentis Bio-EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, therapeutics Ltd., 9 Blenheim Lane, Freeland, Witney Ox- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = fordshire OX29 8AW (GB). HEAL, Jonathan; c/o Ducen- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, tis Biotherapeutics Ltd., 9 Blenheim Lane, Freeland, Wit-KM, ney Oxfordshire OX29 8AW (GB). ML, MR, NE, SN, TD, TG). = (54) Title: CD200 MUTANT AND ITS USES FIGURE 6 Dose response results comparing the inhibition of PMA stimulated oxidative burst in isolated human neutrophils by wild-type CD200-Fc and K130Y = = , \" voy, * = = — 0 = = s 0 f3 a = = X*j 0 a. a A ril 0 5 E P p , • i = CO; • Il Il 7r CI ' 7r CI ' (57) : The invention relates generally to mutant CD200 proteins which bind with greater affinity to the CD200 receptor than ---- wild IN -type CD200, in particular the invention relates to a mutated CD200 protein comprising a mutation at amino acid residue position ,1 130 and/or 131. This invention also relates to a fusion protein comprising the protein as defined herein fused to a non-CD200 protein 0 encoding portion via an optional linker portion, a pharmaceutical composition comprising ei the protein as defined herein and uses thereof. O [Continued on next page] WO 2017/194941 Al MIDEDIMOMOIDEIROIDEMOMOHEIBIOSHIMOVOIMIE Published: — with international search report (Art. 21(3)) — with amended claims and statement (Art. 19(1)) — with sequence listing part of description (Rule 5.2(a))
SG11201809677XA 2016-05-10 2017-05-10 Cd200 mutant and its uses SG11201809677XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (1)

Publication Number Publication Date
SG11201809677XA true SG11201809677XA (en) 2018-11-29

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809677XA SG11201809677XA (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Country Status (15)

Country Link
US (1) US11203628B2 (en)
EP (1) EP3455247A1 (en)
JP (1) JP6997767B2 (en)
KR (2) KR20230025937A (en)
CN (1) CN109219614B (en)
AU (1) AU2017264825B2 (en)
BR (1) BR112018073280A2 (en)
CA (1) CA3023601A1 (en)
EA (1) EA201892554A1 (en)
GB (1) GB201608197D0 (en)
IL (1) IL262846B2 (en)
MX (1) MX2018013778A (en)
SG (1) SG11201809677XA (en)
WO (1) WO2017194941A1 (en)
ZA (1) ZA201807079B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (en) 2019-02-18 2020-12-04 박주현 A manned drone that separates the flight part from the occupant and combines it with an axis
CN110859951A (en) * 2019-09-23 2020-03-06 中国药科大学 Application of CD200 protein and CD200 fusion protein in preparation of psoriasis treatment drugs
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
WO2023214387A1 (en) * 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
WO2023214388A1 (en) * 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
DK1032662T3 (en) 1997-11-07 2006-07-03 Trillium Therapeutics Inc Methods and Compositions for Immunomodulation
WO2000061171A2 (en) 1999-04-13 2000-10-19 Schering Corporation Uses of mammalian ox2 protein and related reagents
AU2001245280A1 (en) * 2000-03-07 2001-09-17 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2429579A1 (en) * 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Truncated cd200
AU2006283532B2 (en) * 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
WO2008089022A2 (en) 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
WO2010120541A2 (en) * 2009-03-31 2010-10-21 University Of Washington Compositions and methods for modulating the activity of complement regulatory proteins on target cells
EP2523976B1 (en) * 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Also Published As

Publication number Publication date
MX2018013778A (en) 2019-08-01
US11203628B2 (en) 2021-12-21
IL262846A (en) 2018-12-31
GB201608197D0 (en) 2016-06-22
CA3023601A1 (en) 2017-11-16
KR102498901B1 (en) 2023-02-10
AU2017264825B2 (en) 2021-04-08
BR112018073280A2 (en) 2019-03-19
CN109219614B (en) 2022-05-24
EP3455247A1 (en) 2019-03-20
WO2017194941A1 (en) 2017-11-16
US20190367580A1 (en) 2019-12-05
EA201892554A1 (en) 2019-04-30
ZA201807079B (en) 2019-07-31
CN109219614A (en) 2019-01-15
IL262846B (en) 2022-10-01
JP2019518788A (en) 2019-07-04
JP6997767B2 (en) 2022-03-04
AU2017264825A1 (en) 2018-11-15
IL262846B2 (en) 2023-02-01
KR20190003761A (en) 2019-01-09
KR20230025937A (en) 2023-02-23

Similar Documents

Publication Publication Date Title
SG11201809677XA (en) Cd200 mutant and its uses
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811432WA (en) Rna for cancer therapy
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201907422RA (en) Anti-tau antibodies and methods of use thereof
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201803642WA (en) Bacteria-based protein delivery
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201903348UA (en) Therapeutic compounds and methods of use thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201806852PA (en) Protein purification